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We have shown previously that at physiologically relevant oxygen
tension (pO2 ' 10 mmHg), NO S-nitrosylates 1 of '50 free cysteines
per ryanodine receptor 1 (RyR1) subunit and transduces a calcium-
sensitizing effect on the channel by means of calmodulin (CaM). It
has been suggested that cysteine-3635 is part of a CaM-binding
domain, and its reactivity is attenuated by CaM [Porter Moore, C.,
Zhang, J. Z., Hamilton, S. L. (1999) J. Biol. Chem. 274, 36831–36834].
Therefore, we tested the hypothesis that the effect of NO was
mediated by C3635. The full-length RyR1 single-site C3635A mutant
was generated and expressed in HEK293 cells. The mutation
resulted in the loss of CaM-dependent NO modulation of channel
activity and reduced S-nitrosylation by NO to background levels
but did not affect NO-independent channel modulation by CaM or
the redox sensitivity of the channel to O2 and glutathione. Our
results reveal that different cysteines within the channel have been
adapted to serve in nitrosative and oxidative responses, and that
S-nitrosylation of the cysteine-containing CaM-binding domain
underlies the mechanism of CaM-dependent regulation of RyR1 by
NO.
The gaseous messenger nitric oxide (NO) has been proposedto exert regulatory effects on ion channels by modifying the
redox state of critical thiols (1–3). NO-sensitive ion channels
include the cardiac and skeletal muscle ryanodine receptors
(RyRs; refs. 4–10), L-type Ca21 channel (11), Na1 channel in
baroreceptors (12), cyclic nucleotide-gated channel (13), Ca21-
or voltage-gated K1 channel (14, 15), and N-methyl-D-aspartate
receptor channel complex (16, 17).
The skeletal muscle Ca21 release channelyryanodine receptor
(RyR1) contains a large number of free thiols whose oxidation
or nitrosylation influences channel function (9, 18–20). RyR1
redox state and activity depend on O2 tension (9), transmem-
brane glutathione redox potential (21), and effector molecules
(Ca21, Mg21) that control RyR1 channel activity (22). Nearly
half of the 404 cysteines within the tetrameric RyR1 channel
complex are maintained in a reduced (free-thiol) state under
redox conditions comparable to resting muscle (9). Changes in
O2 tension dynamically oxidizeyreduce as many as six to eight
thiols per RyR1 subunit and, thereby, control channel respon-
siveness to physiological concentrations of NO. NO increases
RyR1 activity by S-nitrosylation of one thiol per RyR1 subunit,
and this effect is transduced by calmodulin (CaM; ref. 9).
CaM has a dual effect on skeletal muscle Ca21 release channel
activity. CaM activates the channel at Ca21 concentrations below
1 mM, and inhibits the channel at Ca21 concentrations above 1
mM (23). The skeletal muscle Ca21 release channel binds one
CaM per RyR1 subunit in the absence and presence of Ca21,
which suggests that both the Ca21-free (apoCaM) and Ca21-
bound (CaCaM) forms of CaM bind to RyR1 (24, 25). Trypsin
cleavage and analysis (24, 26) and site-directed mutagenesis (27)
suggest that apoCaM and CaCaM have overlapping binding sites
that mask C3635 from reaction with N-ethylmaleimide (24, 26)
and that involve leucine-3624 (27). These data suggest that
C3635 is part of the CaM-binding domain.
In the present study, we tested the hypothesis that C3635 is
responsible for the CaM-dependent effects of NO on RyR1. We
substituted an alanine residue for C3635 and expressed the
mutant protein in HEK293 cells. Chemical analysis and immu-
noblotting with an anti-S-nitrosocysteine antibody revealed in
vitro S-nitrosylation of wild-type (wt) RyR1 but not of the
C3635A mutant. Moreover, functional studies with the mutant
RyR showed a loss of NO responsiveness. These results indicate
that NO mediates its effects on RyR1 by S-nitrosylation of
C3635.
Experimental Procedures
Materials. [35S]CaM (5 Ciymmol; 1 Ci 5 37 GBq) was prepared
by using Tran35S-label (ICN) as described (25). [3H]Ryanodine
(50–100 Ciymmol) was purchased from Perkin–Elmer. Unla-
beled ryanodine and myosin light chain kinase-derived CaM-
binding peptide (CaMBP) were obtained from Calbiochem;
CaM was obtained from Sigma; leupeptin, Pefabloc (a protease
inhibitor), and 3,3-diaminobenzidine substrate kit were from
Roche Molecular Biochemicals. NO gas (purity . 99%, AGA
Specialty Gas, Maumee, OH) was scrubbed to remove O2 and
nitrite by passing it through an argon-purged column filled with
KOH pellets; the gas was then bubbled through a solution of
NaOH. The concentration of NO dissolved in the argon-purged
buffer was determined by using a hemoglobin titration assay (9).
All other chemicals were of analytical grade.
Construction and Expression of C3635A Mutant. The construction of
the full-length rabbit RyR1 cDNA has been described (28). A
2,706-bp fragment (PvuIyNdeI, 8465y11171), excised from a
6.7-kb fragment of RyR1 in pBluescript II KS1 (PvuI-XbaI,
8465y11171) and cloned into pBluescript II KS1 vector, served
as the template for mutagenesis. The C3635A mutation was
prepared by introducing a double base change (TG to GC) by Pfu
DNA polymerase-based chain reaction by using two mutagenic
primers (forward primer: 59-agccgtggtggccGCcttccgtatgacg-39;
reverse primer: 59-cgtcatacggaagGCggccaccacggct-39) and the
QuickChange site-directed mutagenesis kit (Stratagene). The
mutated sequence was confirmed by sequencing and reintro-
duced into the PvuI and XbaI sites of the 6.7-kb fragment in
KS1. The mutated, full-length expression plasmid was prepared
by the ligation of two fragments—ClaIyPvuI and PvuIyXbaI
(containing the mutated sequence)—in the expression vector
pCMV5 (ClaIyXbaI). wt and mutant RyR1 cDNAs were tran-
siently expressed in HEK293 cells by using Effectene (Qiagen,
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Chatsworth, CA), according to the manufacturer’s instructions.
Cells were maintained in high-glucose DMEM containing 10%
(volyvol) FBS at 37°C under a 5% CO2y95% air atmosphere and
plated the day before transfection. For each 10-cm tissue-culture
dish, 6 mg of DNA was used at a DNAyEffectene ratio of 1:5.
Cells were harvested 42–46 hr after transfection, and crude
membrane fractions were prepared as described (29).
Isolation of Skeletal Sarcoplasmic Reticulum (SR) Vesicles. SR mem-
brane fractions enriched with RyR1 were prepared from rabbit
skeletal muscle in the presence of protease inhibitors (100 nM
aprotininy1 mM leupeptiny1 mM pepstatiny0.2 mM phenylmeth-
ylsulfonyl f luoridey1 mM benzamidine) as described (30).
Quantification of RyR1 S-Nitrosothiol (SNO) Content. The SNO
content of the purified wt and C3635A mutant RyR1s was
determined by a photolysisychemiluminescence method as de-
scribed (9).
Electrophoresis and Western Blotting. All procedures were per-
formed under nonreducing conditions. Proteins were denatured
for 5 min at 95–100°C and separated on SDSy3–12% polyacryl-
amide gels and transferred to Immobilon-P membranes (28).
Membranes were blocked in PBS buffer containing 0.05%
Tween-20 and 5% nonfat milk, and transferred proteins were
made to react with either anti-RyR1 monoclonal antibody D110
(29) or an anti-S-nitrosocysteine polyclonal antibody (1:200–
1:500 dilution, Calbiochem). Bound antibodies were detected
with goat anti-mouse or anti-rabbit IgG-horseradish peroxidase-
linked antibody, respectively, with a 3,3-diaminobenzidine sub-
strate kit.
[3H]Ryanodine Binding. Unless otherwise indicated, skeletal SR
vesicles (0.2 mgyml) or microsomal membrane fractions con-
taining the expressed RyR1s (0.4 mgyml) were exposed to
various concentrations of redox reagents and then incubated for
5 hr at 24°C with 5 nM [3H]ryanodine in media containing 0.125
M KCl, 20 mM imidazole (pH 7.0), 0.3 mM Pefabloc, 30 mM
leupeptin, and the indicated concentrations of CaM and free
Ca21. Nonspecific binding was determined by using a 1,000-fold
excess of unlabeled ryanodine. Aliquots of the samples were
diluted with 20 volumes of ice-cold water and placed on What-
man GFyB filters soaked with 2% (wtywt) polyethyleneimine.
Filters were washed with three 5-ml vol of ice-cold 0.1 M KCly1
mM KPipes (pH 7) buffer, and the radioactivity remaining on
the filters was determined by liquid scintillation counting to
obtain bound [3H]ryanodine.
[35S]CaM Binding. Membrane fractions were incubated for 2 hr at
24°C with 5 or 15 nM [35S]CaM in 250 mM KCly20 mM
imidazole, pH 7.0y0.3 M sucrosey0.2 mg/ml BSAy5 mM reduced
glutathione (GSH)y25 mM leupeptiny0.25 mM Pefabloc and
either 5 mM EGTA (for apoCaM binding) or 100 mM free Ca21
(for CaCaM binding). Aliquots were taken for determination of
total radioactivity and centrifuged for 30 min at 30 psi (120,000
3 g) in a Beckman Airfuge (Beckman Coulter) to obtain bound
[35S]CaM. Nonspecific binding of [35S]CaM was determined by
incubating equal amounts of membranes derived from vector or
nontransfected HEK293 cells. In parallel experiments, Bmax
values of [3H]ryanodine binding were determined by a 5-hr
incubation of membrane fractions at 24°C with 30 nM [3H]ry-
anodine in 0.6 M KCly20 mM imidazole, pH 7.0y25 mM leu-
peptiny0.25 mM Pefablocy100 mM free Ca21. Radioactivities
were determined by scintillation counting.
Data Analysis. Results are given as means 6 SD. Significance of
differences of data were analyzed with Student’s t test. Differ-
ences were considered to be statistically significant at P , 0.05.
Results
C3635 Is Responsible for Modulation of RyR1 by NO. We have shown
that at skeletal muscle O2 tension (pO2 ' 10 mmHg), submi-
cromolar NO activates the native RyR1 by S-nitrosylation of one
cysteine per RyR1 subunit, and that activation requires the
presence of CaM. At ambient O2 tension (pO2 ' 150 mmHg),
submicromolar NO neither S-nitrosylated nor activated the
native RyR1 (9). The same strategy was used to explore the
action of NO on the C3635A RyR1 mutant. wt and C3635A
mutant RyR1s were expressed in HEK293, and the effects of a
range of NO concentrations were tested by determining the
[3H]ryanodine-binding levels of the expressed RyR1s at equi-
librium in membrane fractions at pO2 ' 10 mmHg and pO2 '
150 mmHg. Ryanodine is a highly specific plant alkaloid that is
widely used as a probe of channel activity because of its
preferential binding to the open RyR channel states (31, 32). As
shown in Fig. 1A, wt RyR1 was activated by low concentrations
of NO with a peak of [3H]ryanodine binding at 1 mM NO in pO2
' 10 mmHg. In agreement with our previous study with the
native RyR1 (9), NO concentrations greater than 5 mM reversed
the activation of wt RyR1, indicating additional modifications by
NO. No change in activity was observed when membranes were
freed of endogenous CaM (see also Fig. 4) by pretreatment with
1 mM CaMBP followed by centrifugation to remove complexed
CaMBP and CaM (25). Thus, wt RyR1 activation by physiolog-
Fig. 1. C3635A RyR1 does not respond to NO. Specific [3H]ryanodine binding
to membrane fractions prepared from HEK293 cells expressing wt-RyR1 (A) or
mutant C3635A RyR1 (B) was determined in the presence of 10 mM free Ca21
and increasing concentrations of NO in pO2 ' 10 mmHg (white bars) or pO2 '
150 mmHg (black bars). [3H]Ryanodine-binding values, determined as de-
scribed in Experimental Procedures, ranged from 0.05 to 0.15 pmolymg
protein for both wt-RyR1s and C3635A RyR1s. Normalized [3H]ryanodine
binding data (100% in the absence of NO for each condition) are the means 6
SD of five experiments. *, P , 0.05 when compared with controls in pO2 ' 10
mmHg and pO2 ' 150 mmHg.








ical amounts of NO depended on CaM. wt RyR1 channel activity
was not changed by NO at pO2 ' 150 mmHg, and in contrast to
wt RyR1, the C3635A mutant did not respond to NO at either
oxygen tension (Fig. 1B).
We used an anti-S-nitrosocysteine polyclonal antibody to
determine whether NO S-nitrosylated the RyR1 C3635A mutant
channel. The antibody detected a faint signal in the SR control
sample (2NO) (Fig. 2 B and C, lane 2) in a region of the
immunoblot containing the RyR1, as determined by an anti-
RyR1 antibody (Fig. 2 A). Specificity of the antibody for SNO
was provided by treatment with HgCl2 that nearly eliminated the
signal (Fig. 2, odd-numbered lanes). NO (1 mM) significantly
increased the level of S-nitrosylation of the native RyR1 in pO2
' 10 mmHg (Fig. 2B, lane 4) but not pO2 ' 150 mm (Fig. 2C,
lane 4), which is in agreement with our previous study showing
S-nitrosylation of the native RyR1 at low but not ambient oxygen
tension (9). wt RyR1 showed a response to NO comparable to
the native RyR1, which likewise exhibited an increased level of
endogenous S-nitrosylation only in pO2 ' 10 mmHg (Fig. 2 B
and C, lane 12). In contrast, NO did not increase noticeably the
low levels of endogenous immunoreactivity of the C3635A RyR1
mutant at either low or high oxygen tension (Fig. 2 B and C, lanes
6 and 8).
We also measured the extent of S-nitrosylation of the wt and
C3635A mutant RyR1 channels with a photolysisychemilumi-
nescence method (9). wt and C3635A mutant RyR1 membrane
fractions were treated with 1 mM NO at pO2 ' 10 mmHg. The
receptors were solubilized in 1.5% 3-[(3-cholamidopropyl)dim-
ethylammonio]-1-propanesulfonate (CHAPS), without (con-
trols), or after NO treatment for 1 hr at 24°C, and isolated by
sucrose density-gradient centrifugation. Purified, control wt and
C3635A mutant RyR1s showed essentially no signal (,0.01 SNO
per RyR1 subunit). Purified, NO-treated wt and C3635A mutant
RyR1s contained 1.15 6 0.60 and 0.34 6 0.25 SNO per subunit,
respectively (n 5 3), or a difference of ' 1 SNO per subunit.
CaM and Redox Modulation of C3635A. Recent studies have shown
that NO activation of RyR1 depends on the presence of CaM (9).
Moore et al. (26) showed that C3635 is alkylated by N-
ethylmaleimide and that this reaction is blocked by CaM. In the
present study, we examined whether the C3635-to-A substitution
in RyR1 altered the channel’s regulation by CaM and redox-
active molecules. In Fig. 3, CaM binding to wt and binding to the
C3635A mutant RyR1s are compared, by using [35S]CaM con-
centrations that are near and above the dissociation constants of
apoCaM and CaCaM binding to the native, purified RyR1 (25).
Cells expressing wt RyR1 bound '4 apo[35S]CaM and 5
Ca[35S]CaM per [3H]ryanodine-binding site. As there is only one
high-affinity [3H]ryanodine-binding site per RyR1 tetramer,
these ratios correspond to '1 apoCaM- and 1 CaCaM-binding
site per RyR1 subunit. The binding of apo[35S]CaM and
Ca[35S]CaM to C3635A was not different from wt RyR1, which
indicates that C3635 is not crucial for conferring high-affinity
apoCaM and CaCaM binding.
Next, we examined whether the C3635A mutation affected
either CaM inhibition of [3H]ryanodine occupancy or CaM-
dependent modulation of RyR1 activity by NO (Fig. 4). wt and
C3635A mutant RyR1 membrane fractions were pretreated with
1 mM CaMBP to sequester endogenous CaM (25) or were
preincubated with 1 mM exogenous CaCaM before being ex-
posed to 1 mM NO in pO2 ' 10 or pO2 ' 150 mmHg.
Pretreatment with CaMBP increased [3H]ryanodine binding,
whereas the addition of exogenous CaCaM had an inhibitory
effect. These results are in agreement with previous studies
showing the inhibition of RyR1 activity by CaCaM (25). Fig. 4
further shows that the C3635A mutation did not eliminate
inhibition of RyR1 activity by CaCaM. Fig. 4 also shows that in
the CaMBP pretreated samples, 1 mM NO had no effect on
[3H]ryanodine binding. In the presence of 1 mM CaM, however,
NO increased wt RyR1 activity in pO2 ' 10 mmHg but not in
pO2 ' 150 mmHg, which is in agreement with studies on the
native RyR1 (9). NO did not activate significantly the mutant
channel in the presence of CaM in either oxygen tension. Thus,
C3635 is required for the CaM-dependent modulation of RyR1
by NO.
To address the question of whether C3635 is required for the
general effects of redox-related molecules on the channel, we
explored the effects of oxygen tension and GSH or oxidized
glutathione (GSSG) on wt and C3635A mutant RyR1 activities
(Fig. 5). We found that in both wt and mutant RyR, [3H]ryano-
dine binding was higher in ambient (pO2 ' 150 mmHg) than in
biologically relevant muscle oxygen tension (pO2 ' 10 mmHg),
Fig. 2. Immunoblots of nitrosocysteine. Skeletal SR vesicles (lanes 1–4, 10 mg
each lane) and cell membrane fractions containing C3635A RyR1 (lanes 5–8, 40
mg each lane) or wt-RyR1 (lanes 9–12, 40 mg each lane) were incubated for 1
hr at 24°C in pO2 ' 10 mmHg or pO2 ' 150 mmHg in the presence of 1 mM NO.
Anti-nitrosocysteine negative controls (treated with 0.1 mmHgCl2, odd-
numbered lanes), samples without NO (lanes 2, 6, and 10), and samples treated
with 1 mM NO (lanes 3 and 4, 7 and 8, 11 and 12) at pO2 ' 10 mmHg (B) and
pO2 ' 150 mmHg (C) were separated by SDSy3–12% PAGE gradient. The
proteins were transferred to Immobilon-P membranes overnight at 4°C. A
polyclonal anti-nitrosocysteine antibody was used to detect an S-nitrosylation
signal in the protein band region of RyR1 probed with D110 monoclonal
anti-RyR1 (A). The data are representative of three experiments.
Fig. 3. [35S]CaM binding to wt-RyR and C3635A RyR. Membrane fractions
prepared from HEK293 cells and expressing wt-RyR1 (white bars) or C3635A
mutant RyR1 (black bars) were incubated with 5 or 15 nM [35S]CaM and either
5 mM EGTA or 100 mM Ca21. The ratios of [35S]CaM-binding values to maximal
binding values of [3H]ryanodine are shown. Maximal values of [3H]ryanodine
binding were determined as described under Experimental Procedures. Data
are the means 6 SD of three experiments.
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and, likewise in both cases, [3H]ryanodine binding was decreased
by GSH and increased by GSSG (irrespective of O2 tension).
Similar data have been reported when SR vesicles were used (9,
20, 33). In other studies, we found that the mutant channel
displayed a Ca21 activationyinactivation profile (31, 32) that was
essentially identical to wt RyR1 (data not shown). Taken to-
gether, the results of Figs. 4 and 5 suggest that the C3635A
mutation does not eliminate the channel’s response to physio-
logical effectors, in particular, Ca21, CaM, oxygen tension, and
GSH or GSSG.
Discussion
We report that a single cysteine (C3635) is responsible for
sensitizing the skeletal muscle Ca21 release channel to NO.
This finding is particularly remarkable given the unusually
large number of reactive cysteines ('50 free thiols per RyR1
subunit) in the channel. S-nitrosylation of a single cysteine also
has been shown to be necessary and sufficient for NO respon-
siveness in cyclic nucleotide-gated channels (13), the N-
methyl-D-aspartate receptor-channel complex (17), p21 ras
(34), and hemoglobin (35). The site of posttranslational mod-
ification in these proteins is identified by an acid–base con-
sensus motif, revealed in the primary sequence, i.e., cysteine
is f lanked on either side by lysine, arginine, histidine, aspar-
tate, or glutamate [and, in the prototype case, is followed by an
acidic amino acid residue, aspartate or glutamate, at the
11 (C-terminal) position] (13, 17, 36). The C3635 in RyR1
(AVVACF; refs. 26 and 37) lacks f lanking acidic or basic
residues. It has been shown recently, however, that the acid–
base motif for S-nitrosylation may emerge from the tertiary
structure, as illustrated in the cases of methionine adenosyl-
transferase (38) and caspase-3 (39) or even from protein–
protein interactions. In addition, it has been suggested that
hydrophobic compartments within or between proteins oper-
ationally define a ‘‘hydrophobic motif’’ for S-nitrosylation (40,
41); C3635 sits in such a hydrophobic pocket (41).
RyR1 was S-nitrosylated at low (10 mmHg) but not high (150
mmHg) O2 tension. We have shown that the O2 concentration
determines the redox state of six to eight thiols per RyR subunit.
Therefore, oxygen can be viewed as producing a preparatory
modification of the channel that serves to facilitate S-
nitrosylation. Our working model is that a redox-driven confor-
mational change in the channel creates a local hydrophobic
domain to concentrate NOyO2 for the purposes of generating
nitrosylating equivalents. That is, the S-nitrosylation reaction
likely occurs through intermediates formed by NO and O2 (42)
and is accelerated in a hydrophobic compartment where NO and
O2 concentrate (41–43).
Fig. 4. Effects of CaM and NO on wt-RyR1 and C3635A RyR1 activities.
Membrane fractions containing wt-RyR1 (A) or C3635A mutant RyR1 (B)
(control) were preincubated with 1 mM CaMBP to sequester endogenous CaM
(CaMBP) or were preincubated with 1 mM exogenous CaM (CaM). [3H]Ryano-
dine binding was assayed with 10 mM free Ca21 in the absence (white bars) or
the presence (black bars) of 1 mM NO in both pO2 ' 10 and pO2 ' 150 mmHg.
Normalized [3H]ryanodine-binding data, expressed as percent of the binding
values of membranes pretreated with CaMBP (NO), are the means 6 SD of four
to six experiments. *, P , 0.05 when compared with controls in pO2 ' 10 and
pO2 ' 150 mmHg.
Fig. 5. Effect of oxygen tension and GSHyGSSG on wt-RyR1 and C3635A RyR1
activities. Specific [3H]ryanodine binding to membrane fractions prepared
from HEK293 cells expressing wt-RyR1 (A) or C3635A RyR1 (B) was determined
in 10 mM free Ca21 medium in the absence or presence of 5 mM GSH or 5 mM
GSSG and either in pO2 ' 10 mmHg (white bars) or pO2 ' 150 mmHg (black
bars). [3H]Ryanodine-binding data are the means 6 SD of three to six exper-
iments. *, P , 0.05 compared with the controls in pO2 ' 10 mmHg and ' 150
mmHg, respectively. #, P , 0.05 compared with controls in pO2 ' 10 mmHg.








S-nitrosylation of wt and C3635A mutant RyR1 was moni-
tored with an anti-nitrosocysteine polyclonal antibody and by
photolysis–chemiluminescence. Although the antibody provides
a rapid and relatively sensitive means of detecting SNO groups
in RyR1, we offer a word of caution because the antibody also
detected a faint signal in the wt and C3635 control samples
(2NO), although a more sensitive chemical analysis failed to
confirm the presence of SNO groups. The finding that prior
treatment with HgCl2 nearly eliminated these background sig-
nals suggests that the antibody also recognizes the unmodified
thiol (and surrounding amino acid residues), although with much
lower affinity.
The RyR1 C3635A mutation did not seem to introduce major
global protein conformational changes, as the mutant channel
showed a Ca21 activationyinactivation profile comparable to wt
RyR1. The functional consequences of the C3635A mutation
also were assessed in CaM-binding studies and by the response
to GSHyGSSG. CaM-binding studies with synthetic peptides
(44) and site-directed mutagenic analysis (27) indicated that
C3635 is a part of or near an RyR1 CaM-binding site that is partly
shared by apoCaM and CaCaM. Moore et al. (26) found that
N-[3H]ethylmaleimide labeling of C3635 is blocked by CaM, and
conversely, that N-ethylmaleimide interferes with apo[35S]CaM
binding, which suggested that C3635 may be important for CaM
binding. Our data show that C3635A binds apo[35S]CaM and
Ca[35S]CaM indistinguishably from wt RyR, and, therefore,
indicate that the global conformation of the CaM-binding site is
largely unchanged by mutagenesis, and that C3635 is not re-
quired for CaM binding. Also, we have shown that SNO mod-
ification, of what we now know to be C3635, does not displace
CaM (9). A likely explanation for the difference between our
results and those of Moore et al. (26) is that alkylation with
N-ethylmaleimide introduces a bulky group at C3635, whereas
mutagenesis and S-nitrosylation do not. Other studies have
shown that RyR1 contains a large number of thiols whose redox
state is controlled by oxygen tension and GSHyGSSG (9, 20–22,
33). We find that the C3635A mutation did not change the basic
redox characteristics of RyR1 either; i.e., neither modulation by
O2 tension nor modulation by glutathione is altered (Fig. 5).
Taken together, these data suggest that C3635 does not contrib-
ute significantly to the redox modulation of RyR1 by glutathione
or O2.
In conclusion, our studies show that a single amino acid
substitution (C3635A) abolishes regulation of the skeletal mus-
cle Ca21-release channel by physiological concentrations of NO.
C3635 is located within or near the CaM-binding domain of
RyR1, which provides a mechanistic basis for the finding that NO
regulation is CaM dependent and, more generally, implies that
S-nitrosylation and CaM modulation of the RyR are irrevocably
linked. Our data also rationalize the observation that S-
nitrosylation of 1 of 50 thiols per RyR subunit can profoundly
regulate the channel. It is intriguing to note that activation of
constitutive NO synthase also depends on CaM. Thus, both the
substrate of S-nitrosylation (RyR) and the catalytic source of
S-nitrosylating equivalents (NO synthase) are regulated by the
binding of CaM.
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